Background:Although factor Xa inhibitors have become a popular choice for chronic oral anticoagulation, effective drug reversal remains difficult due to a lack of specific antidote.
Direct oral anticoagulants (DOACs) have become an increasingly popular treatment option for patients requiring chronic anticoagulation in recent years.
Objective: This study investigated the percentage of patients who achieved hemostasis with 4-factor prothrombin complex concentrate (4-factor PCC) 35 U/kg. The primary end point was to determine the effect of 4-factor PCC 35 U/kg on bleeding progression, assessed using computed tomography.
The aim of this study was to compare the efficacy, safety, and cost-effectiveness of 3-factor prothrombin complex concentrate vs 4-factor prothrombin complex concentrate in trauma patients requiring reversal of oral anticoagulants.
Background: Prothrombin complex concentrates (PCCs) are drug products containing varying amounts of vitamin K-dependent coagulation factors II, VII, IX, and X. The evidence comparing 3-factor PCC (3-PCC) versus 4-factor PCC (4-PCC) for warfarin reversal is conflicting.
Direct oral anticoagulants (DOACs) can be an appealing treatment option for patients in need of chronic anticoagulation.
Reversal of warfarin-induced coagulopathy after traumatic injury may be done exclusively with prothrombin complex concentrates (PCCs).
Review our recent article 'Reversal of warfarin-associated major haemorrhage: activated prothrombin complex concentrate versus 4-factor prothrombin complex concentrate.
This study from Rimsans et al. explores the safety and effectiveness of the use of four factor prothrombin complex concentrate for warfarin reversal.
This observational study analysed the notes of 89 patients who underwent reversal of warfarin in an emergency scenario.